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I
t is commonly admitted that the glyce-
mic control of patients with type 2 dia-
betes proceeds from a complex
“alchemy”inwhichtherespectivecontribu-
tions of both fasting and postprandial glu-
cose are still a subject of debate (1). A1C,
whichremainsthegoldstandardforassess-
ingglucosehomeostasis,isanintegrationof
both fasting and postprandial glucose vari-
ations over a 3-month period (2). From a
mathematical point of view, the theory can
be formulated as follows (3):
[A1C]
0–3 months  0
3 monthsFPG t dt
 0
3 months PPG t dt
where FPG (t) and PPG (t) are the time
courses of fasting and postprandial glu-
cose, respectively.
Asaconsequence,theglycemiccontrol
ofpatientswithtype2diabetescanbesche-
matically depicted by the “glucose triad,”
whose components are as follows: A1C,
fasting, and postprandial glucose levels. At
present, and even though the debate re-
mains wide open, it seems that the best as-
sessmentofglycemiccontrolisprovidedby
the determination of the three above-
mentioned components. Most recommen-
dations that have been published by
medical organizations in different countries
takeintoaccountthethreeparameters,even
though the position statements differ
around the world, but also within the same
country (4).
IMPORTANCE OF THE
FOUR-POINT DIURNAL
GLYCEMIC PROFILE
A tool for integrating the different
periods of daytime
Whereas many physicians continue to
emphasize fasting glucose and A1C to
guide management of diabetes, observa-
tional studies have indicated that glucose
testing at postprandial and postabsorp-
tive time points could play an important
role (5,6). For instance, lessons from
physiology tell us that humans spend half
of their lives in postprandial states (7,8).
The postprandial state, with respect to
glucose, is deﬁned as a 4-h period that
immediately follows ingestion of a meal
(7). During this period, dietary carbohy-
drates are progressively hydrolyzed
through several sequential enzymatic ac-
tions. Even though the insulin response
rapidly reduces the postprandial glucose
excursion with a return to baseline levels
within2h,theoverallperiodofabsorp-
tion has approximately a 4-h duration
that corresponds to the postprandial
state. The postabsorptive state consists of
a 6-h period that follows the postprandial
period. During this time interval, glucose
concentrations remain within a normal
range in nondiabetic individuals through
the breakdown of the glycogen (glycogeno-
lysis) stored during the postprandial pe-
riod. The “real” fasting state commences
only at the end of the postabsorptive pe-
riod(10–12hafterthebeginningofthe
last meal intake). During the fasting state,
plasma glucose is maintained at a near-
normal level by the gluconeogenesis: glu-
cose derived from lactate, alanine, and
glycerol. Therefore, it appears that in a
nondiabetic patient who takes three
mealsperdayatrelativelyﬁxedhours,the
24-hperiodofthedaycanbedividedinto
three periods corresponding to fasting,
postprandial, and postabsorptive states.
The postprandial period (4 h each) is
equal to 12 h and covers a full half-day
periodoftime(Fig.1)(8).Therealfasting
periodisonlylimitedtoa3-to4-hperiod
of time at the end of the night. Further-
more, taking into account the overlap
between the postprandial and postab-
sorptiveperiods,itcanbeassertedthatall
the remaining parts of daytime corre-
spond to postabsorptive states (Fig. 1).
Although the postprandial glucose excur-
sions are usually higher and last for
longer,withgreatervariability,inpatients
with diabetes compared with those in
healthy individuals (9), these three peri-
ods remain present in patients with dia-
betes. Therefore, the ideal regimen for
assessing blood glucose variations over
daytime should include one or several
time points of self-monitoring of blood
glucosewithineachofthesethreeperiods
(10). Accordingly, for the last few years,
we have been advised to use the four-
point glycemic proﬁle as an investigative
tool for the monitoring of blood glucose
in patients with type 2 diabetes (5,6). The
prebreakfast glucose is a reﬂection of
the real fasting state, the mid-morning
and the 2-h postlunch values can be con-
sidered to reﬂect postprandial periods,
and ﬁnally the 5-h postlunch glucose
(extended postlunch value) is a marker
of a postabsorptive period (7,8). It is
obvious that, in non–insulin-using type
2 diabetic patients, such a four-point
glycemic proﬁle should not be regularly
performedeveryday.Forthatreason,in
these patients, we have limited the use
of self-monitoring of blood glucose to
once a day, but we recommend to rotate
glucose testing at the different times of
the day over a 4-day period to have a
broader picture of the glucose ﬂuctua-
tions over daytime (10).
A tool for establishing the
contributions of fasting and
postprandial glucose to overall
hyperglycemia in patients with type
2 diabetes
In recent years, new data have provided
further information for the ongoing de-
bate over whether A1C, fasting glucose,
and postprandial glucose contribute
equally or not to the overall hyperglyce-
mia in type 2 diabetes (6,11–14). A few
years ago, in non–insulin-treated type 2
diabetic patients, we found that
postlunch and extended postlunch
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withoverallglycemiccontrolasestimated
from A1C than did prebreakfast and pre-
lunch glucose levels (12). In the same
type of patients, Bonora et al. (13) re-
ported that preprandial plasma glucose
concentrations were related to A1C more
strongly than postprandial concentra-
tions. In an analysis of a dataset collected
in the Diabetes Control and Complica-
tions Trial, Rohlﬁng et al. (14) reported
that better correlation with A1C was ob-
tained for postlunch and mean daily glu-
cose concentrations. These study-to-
study discrepancies are certainly
confounding information for clinical
practice. By contrast, from a scientiﬁc
point of view, these differences are not
surprising, since it is well known that the
multiple regression analysis used for
studying the relationship between A1C
and glucose values at different times is an
unstable model when explanatory vari-
ables, i.e., the glucose values in the
present example, are intercorrelated. To
provide a correct answer, we used a dif-
ferent methodology that consisted of cal-
culating two incremental areas under a
four-point diurnal glycemic proﬁle from
8:00 A.M. to 5:00 P.M., with two interme-
diary time points at 11:00 A.M. and 2:00
P.M. (6). The ﬁrst incremental area was
calculated above a baseline level equal to
the fasting plasma glucose value and was
therefore considered a reﬂection of the
postprandial responses to breakfast and
lunch. The second one was calculated
above a baseline level equal to 6.1 mmol/l
(110 mg/dl), reﬂecting the increases in
bothfastingandpostprandialplasmaglu-
cose. The baseline value of 6.1 mmol/l
was chosen because this threshold had
been deﬁned as the upper limit of normal
plasma glucose at fasting or preprandial
times by the American Diabetes Associa-
tion up to 2003 (15) i.e., before the revi-
sion for the 2004 recommendations (16).
Therefore, the difference of the two pre-
ceding areas can be considered an assess-
ment of the increment in fasting plasma
glucose values. Using this model of calcu-
lation, we have shown that regardless of
the quality of the diabetic control, post-
prandial glucose made a substantial con-
tribution to the overall hyperglycemia.
However, when patients were divided
into ﬁve groups, according to the quin-
tiles of A1C, we found that postprandial
glucose levels made the highest contribu-
tion (70%) in the lower quintile (A1C
7.3%), i.e., in patients with well-
controlled to moderately controlled diabe-
tes (6). By contrast, fasting hyperglycemia
appeared as the main contributor to the
overall diurnal hyperglycemia in patients
with poorly controlled disease (A1C
9.3%). For all patients who had A1C
levels ranging between 7.3 and 9.3%, the
contributions of fasting and postprandial
hyperglycemia were approximately
equivalent. These results seem to concili-
ate the controversial data that were ob-
served in the literature and it can be
concluded that the respective contribu-
tions of fasting and postprandial can be
depicted by a continuous spectrum from
fairly to poorly controlled patients with
type 2 diabetes.
A tool for simplifying the
recommendations: the trilogy of
“sevens”
By analyzing and comparing the recom-
mendations in 13 countries, the authors
of the AGREE study concluded that de-
spite disparities in guidelines around the
world, there exists a high degree of inter-
national consensus—when the recom-
mendations are limited to both A1C and
fasting glucose concentrations (4). At
present,twolevelsofA1Careusuallyrec-
ognized as threshold values for satisfac-
torydiabeticcontrol:7%fortheAmerican
Diabetes Association (17) and 6.5% for
the American College of Endocrinologists
(18) and the International Diabetes Fed-
eration (19). In terms of fasting glucose,
recommended goals are set within a 70–
130mg/dl(3.9–7.2mmol/l)rangeforthe
American Diabetes Association (17) and
at 110 mg/dl (6.1 mmol/l) and 100
mg/dl (5.5 mmol/l) for the American Col-
lege of Endocrinologists (18) and the In-
ternational Diabetes Federation (19),
respectively. For postprandial glucose
threshold values, large discrepancies are
observed. For the American Diabetes As-
sociation, the postprandial glycemic
threshold value has been set at 180 mg/dl
(17). This value corresponds to the upper
limit that was chosen in patients who
were allocated to the intensively treated
group of the DCCT (20). For the Ameri-
can College of Endocrinologists (18) and
the International Diabetes Federation
(19), the recommendation is to maintain
postprandial glucose values below 140
mg/dl. The selection of this value was
mainlybasedonthefactthat140mg/dlis
the cutoff value for deﬁning the impaired
glucosetoleranceatthesecondhourofan
oral glucose tolerance test.
The variability in the recommenda-
tions results in difﬁculties for diabetes
management. Trying to struggle with the
jumble of recommendations and values is
obviously more complicated for health
care providers than memorizing a single
Figure 1—Duration of the postprandial, postabsorptive, and fasting states. The postprandial and
the postabsorptive states last for 4 and 6 h, respectively. Therefore, the cumulative duration of
postprandial state is 12 h, which is equivalent to a full half-day period of time, and the “real”
fasting state is limited to a 3-h time interval at the end of the night.
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should be as simple as possible. An an-
swertothisproblemcanbeobtainedfrom
data that we have previously published
(21).
By analyzing the four-point diurnal
glucoseproﬁlesin480non–insulin-using
type2diabeticpatients,wetestedtheper-
formance of plasma glucose at each time
point to detect a cutoff value that deﬁnes
the quality of patients’ diabetic control as
estimated from A1C levels. The tests were
performed at a 7% threshold of A1C, a
value less than this level being considered
as a reference for good or satisfactory di-
abeticcontrol(17).Sensitivitiesandspec-
iﬁcities for predicting the quality of
diabetic control were calculated at differ-
ent levels of plasma glucose using step-
by-step increments of plasma glucose
from low to high values.
The most important result of this
study was that a value of 7 mmol/l mea-
sured at 2 h after lunch appeared to be
the optimal threshold value for predict-
ing treatment success deﬁned by high
speciﬁcity (90%) A1C levels of 7%.
By considering ﬁrst that the criteria for
the diagnosis of diabetes is a fasting
plasma glucose level 7 mmol/l and
second that 7% has, for a number of
years, been the American Diabetes As-
sociation’s A1C threshold value for sat-
isfactory diabetic control (17), we
suggest that these two number “sevens”
can be joined by an additional post-
prandial “seven” to complete the series.
As a consequence, the “glucose triad”
could be translated for clinical purpose
into the trilogy of “sevens” (Fig. 2) that
integrates a cluster of measures, includ-
ing diagnosis (7 mmol/l glucose at
fasting), interventional threshold val-
uesforcompletingtreatment:A1Cgoals
7% and postprandial glucose targets
7 mmol/l at 2-h after lunch. This
“seven” rule is certainly easier to re-
member than many recommendations
that have been made around the world
(3).
However, all these recommendations
shouldberevisitedonthebasisofthenew
perspectives raised by the analysis of the
results obtained in the three main con-
trolledtrialsthatwererecentlypublished:
the ACCORD (22), ADVANCE (23), and
VADT Diabetes (24) trials. As the AD-
VANCE results (23) indicate a small but
incremental beneﬁt in microvascular out-
comeswithA1Clevelsascloseaspossible
tonormal,itissuggestedthat,forpatients
in whom the treatment is not at risk of
hypoglycemic episodes or other adverse
effects, the general goal can be7% (25).
Such patients include those with short
durationofdiabetes,longlifeexpectancy,
and no signiﬁcant cardiovascular disease.
By contrast, the results of the ACCORD
study(22)seemtoindicatethatlessstrin-
gent goals than the general target of 7%
may be more appropriate in patients
treatedwithsuchhypoglycemicagentsas
sulfonylureas and/or insulin that are at
risk of producing severe hypoglycemic
events. More ﬂexible recommendations
should also be applied to patients who
have a limited life expectancy or who
exhibit advanced micro- or macrovas-
cular complications (25). As a conse-
quence, the question is to know
whether a future reevaluation of the
fasting and postprandial targets will not
become necessary in patients exhibiting
an increased risk for adverse events.
Such changes should take into account
thenewdataonthecorrelationbetween
A1C and average glucose levels (26).
The relationship indicates that a 6%
A1C level is equivalent to a 126 mg/dl
mean glucose concentration and that
each 1% increment of A1C corresponds
to a 29 mg/dl increase in mean glucose
concentration. However, these correla-
tions remain unable to provide a mea-
sure of glycemic variability and/or
hypoglycemia (27).
IMPORTANCE OF
CONTINUOUS GLUCOSE
MONITORING SYSTEMS
A tool for improving our knowledge
on the pathophysiology of type 2
diabetes
Type 2 diabetes is a disease characterized
by three main abnormalities (28): 1) a de-
fectof-cellfunction(29,30),2)astateof
insulinresistance(31),and3)anoverpro-
duction of glucose by the liver (32). De-
spite that currently available oral
hypoglycemicagentsareabletotargetde-
ﬁciencies in either the endogenous insu-
lin secretion or the insulin sensitivity at
differenttargetsites,theattainmentofsat-
isfactory diabetes control becomes more
and more difﬁcult the longer the duration
of the disease (9).
By analyzing continuous glucose pat-
ternsover24h,werecentlydemonstrated
that the deterioration of glucose ho-
meostasis can be approximated to a
three-step process (9). The ﬁrst step
correspondstoalossinpostprandialcon-
trol that occurs in patients with A1C lev-
els between 6.5 and 6.9% and with mean
diabetes duration of 4.4 years. As men-
tioned above, the second step is charac-
terized by a deterioration of the glycemic
control during the pre- and postbreakfast
periodsinpatientswhoexhibitA1Clevels
between 7 and 7.9% and who have mean
diabetes duration of 8.4 years. The ﬁnal
step in the deterioration of diabetic con-
trol occurs generally beyond the end of
theﬁrstdecadeofdiabetesdurationandis
represented by a chronic sustained basal
hyperglycemia over both nocturnal and
interprandial periods and excess post-
prandialglycemia.Inconclusion,thenat-
ural history of the worsening of
dysglycemia in type 2 diabetes is marked
by an early loss of prandial glycemic con-
trol that precedes a deterioration of basal
hyperglycemia. This deterioration
progresses from a period corresponding
to a short time interval limited to the end
of the overnight fast up to an extended
period that covers the nocturnal and in-
terprandialperiodsconsideredasawhole
(9). The prebreakfast glucose deteriora-
tion that occurs at the end of the over-
night fast is known as the “dawn
phenomenon” (33) and is mainly ex-
plained by the circadian variation of the
hepatic glucose production that starts to
rise in the evening and reaches a peak to-
wardtheendofthenocturnalperiod(32).
These abnormal high glucose excursions
that are observed after breakfast can be
Figure 2—How to translate the “glucose triad” into the trilogy of “sevens.”
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enon,” which is due to the remnant effect
of the hepatic glucose overproduction
during the morning period in combina-
tion with the dietary intake of carbohy-
drates at breakfast. The “dawn” and the
“extended dawn” phenomena are two
main causes of failure in the diabetic con-
trolofmanypatientswithtype2diabetes,
especially those who have A1C levels
rangingfrom7to8%andwhoarealready
treated with maximal doses of oral hypo-
glycemic agents. Such observations help
us to understand why type 2 diabetes, a
relentless progressive disease, requires
advancesfrommonotherapywithoralan-
tidiabetic agents to combination therapy
using multiple oral agents and ﬁnally in-
sulin replacement without undue delay
(34).
A tool for choosing between insulin
regimens in patients suffering from
severe insulin deﬁciency
Insulinshouldbeimplementedassoonas
oral hypoglycemic agents at maximal
doses do not achieve satisfactory diabetic
control (34). At present, there is little
doubt that patients with a sustained level
of A1C 8% should be treated with insu-
lin. Because in these patients basal hyper-
glycemia is preponderant over prandial
hyperglycemia, insulin regimens based
on basal insulin should be preferred to
prandialinsulinatinitiationoftheinsulin
therapy. If the target cannot be achieved,
premeal boluses of rapid insulin analogs
should be added, especially before the
meals that result in the more pronounced
glycemic excursions. The problem is
slightly more complex in those patients
who exhibit A1C levels between 7 and
8%. In this situation, most patients are
reluctant to being treated with insulin.
Furthermore, despite recent publications
of more stringent recommendations,
many physicians delay insulin treatment
until further deterioration in A1C occurs.
The new recommendations (34) indicate
that insulin treatment should be initiated
as soon as A1C remains above 7%, with
maximal doses of oral hypoglycemic
agents combining insulin sensitizers
(metformin  glitazone) with an insulin
secretagogue. These recommendations
are in agreement with our data, since the
mean interval of time that separates the
moment at which A1C levels reach 7 and
8% is 4 years (9), a duration that is not
negligible in terms of risk for develop-
mentorprogressionofdiabeticcomplica-
tions. At present, it is recommended to
start insulin with one injection of a long-
acting insulin analog before dinner or at
bedtime (35). With such a regimen, the
insulin action reaches a maximum over a
periodcorrespondingtothedawnandex-
tended dawn phenomena, i.e., over a pe-
riod that covers the end of the overnight
fast and the postbreakfast period (9). In
patients with A1C ranging between 7 and
8%, plasma glucose values over this time
interval are usually more elevated than at
any other period of daytime. However,
this group of patients can be divided into
two subsets according to whether pre-
breakfast glucose levels were lower or
greater than 126 mg/dl (7 mmol/l). Most
patients (more than two-thirds) had glu-
cosepatternswithbotha“dawn”and“ex-
tended dawn” phenomena (Fig. 3) and
shouldbetreatedwithasingleinjectionof
long-acting insulin analog before dinner
or at bedtime. In less than one-third, pre-
breakfast glucose values remained below
126mg/dl(Fig.3).Inthislattersubgroup
of patients, the dawn phenomenon was
absent. Nevertheless, these patients with
near-normal glycemia before breakfast
experience abnormal postbreakfast ex-
cursions,whichresultinsustainedhyper-
glycemia over the entire morning period.
To combat this glycemic proﬁle, which is
limited to the postbreakfast period, it is
probably preferable to administer a small
bolus of a rapid-acting insulin analog at
prebreakfast than a long-acting insulin
analog before dinner or at bedtime. Con-
tinuous glucose monitoring can be a use-
ful tool for guiding the choice between
these two insulin regimens. When this
type of monitoring is not available, the
clinician can use, as a surrogate, the glu-
cose values at prebreakfast and at 2-h
postbreakfast times. The observation of
concomitant elevation of both pre- and
postbreakfast glucose suggests that the
basalhyperglycemiashouldbecontrolled
Figure3—The24-hrecordingsfromthecontinuousglucosemonitoringsysteminnon–insulin-usingtype2diabeticpatientswithA1Cbetween7and
8%. The patients were divided into two subgroups according to whether plasma glucose at fasting was higher (n 	 25) or lower (n 	 7) than 126
mg/dl (7 mmol/l).
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linregimenshouldbeinitiatedwitheither
intermediate-acting insulin or a long-
acting insulin analog. By contrast, an ele-
vated postbreakfast level with a near-
normal fasting glucose level indicates that
a bolus of rapid insulin analog should be
administeredbeforebreakfasttobluntthe
postbreakfast glucose excursions. Tailor-
ing the insulin replacement rather than
adopting standardized insulin strategies
is a more logical approach to achieve sat-
isfactory metabolic control.
WHY ARE BOTH GLUCOSE
AND A1C
DETERMINATIONS
COMPLEMENTARY?— In the
present review, we have mainly devel-
opedtheglucosesidefortargetingthegly-
cemic control. However, it should be
mentionedthatbothglucoseandA1Cde-
terminations are important for the moni-
toring and management of patients with
diabetes.Forinstance,A1Clevelsprovide
useful information on the respective con-
tributions of postprandial and basal hy-
perglycemia to the overall hyperglycemia
of patients with type 2 diabetes (6). Be-
cause postprandial glucose is a predomi-
nant contributor in patients with A1C
levelsrangingfrom6.5to7.5%,itismore
logical to implement treatment aimed at
reducing postprandial excursions in such
patients to achieve A1C levels below
6.5%. By contrast, in those patients who
exhibitA1Clevelsabove7.5%,ithasbeen
demonstrated that the basal hyperglyce-
mia becomes predominant, and therefore
anytreatmenttoimprovediabetescontrol
should be initiated by using medications
that mainly act on fasting and interpran-
dial glucose. For instance, the level of
A1C should dictate the choice of an insu-
lin secretagogue as second-line or third-
line therapy, according to whether the
patient is already treated with metformin
alone or with combinations of metformin
and glitazone. In patients who have an
A1C 7.5%, it is more appropriate to se-
lectasulfonylurea,whichismoreefﬁcient
than other insulin secretagogues on the
fasting and more generally on the basal
hyperglycemia. By contrast, in those pa-
tients who have A1C 7.5%, gluco-
dependent insulinotropic agents such as
glucagon-likepeptide-1analogsordipep-
tidyl peptidase IV inhibitors would be a
better choice, since these medications are
mainly active on postmeal glucose excur-
sions (36).
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